首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Nutrition metabolism and cardiovascular diseases

缩写:NUTR METAB CARDIOVAS

ISSN:0939-4753

e-ISSN:1590-3729

IF/分区:3.7/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引3966
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Ching-Yao Tsai,Yun-Ju Lai,Shen-Shong Chang et al. Ching-Yao Tsai et al.
Background and aims: Population-based evidence on the association between fruit and vegetable consumption and the risk of rapid kidney function decline is limited and inconsistent. We investigated the impact of fruit and ...
Hee Joon Choi,Jae-Min Park,Youn Huh et al. Hee Joon Choi et al.
Background and aim: Food insecurity, which is inadequate access, availability and use of food, has been associated with obesity. This study investigated the relationship between food insecurity and obesity-related comorbi...
Mateus L Macena,Micnéias R Pereira,Dafiny R Silva et al. Mateus L Macena et al.
Background and aims: To evaluate the effectiveness and metabolic effects of restricting UPF consumption in individuals with obesity undergoing energy restriction. ...
Carmine Izzo,Albino Carrizzo,Fausto Acernese et al. Carmine Izzo et al.
Background and aims: Type II Diabetes Mellitus (T2DM) is a frequent comorbidity among severely obese individuals undergoing bariatric surgery evaluation. This study aimed to investigate clinical and demographic associated...
Fabio Lauria,Annarita Formisano,Marika Dello Russo et al. Fabio Lauria et al.
Aims: The Mediterranean diet (MedD) is associated with improved metabolic health and modulation of gut microbiota (GM), both relevant to preventing type 2 diabetes (T2D) and cardiovascular disease (CVD). This systematic r...
Stefania Paolillo,Federica Marzano,Dario Bruzzese et al. Stefania Paolillo et al.
Aims: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as key disease-modifying agents for patients with heart failure (HF) and chronic kidney disease (CKD), regardless of diabetes status. Despite their wel...